Literature DB >> 33299837

A new tool for estimating liver cancer risk after a hepatitis C virus cure.

Hamish Innes1, William L Irving2.   

Abstract

Entities:  

Year:  2020        PMID： 33299837      PMCID： PMC7720061          DOI： 10.21037/hbsn.2020.03.08

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  14 in total

1.  Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Steven M Asch; Yumei Cao; Liang Li; Hashem B El-Serag
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

2.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.

Authors:  George N Ioannou; Pamela K Green; Lauren A Beste; Elijah J Mun; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

Review 3.  Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?

Authors:  Tarik Asselah; Patrick Marcellin; Raymond F Schinazi
Journal:  Liver Int       Date:  2018-02       Impact factor: 5.828

4.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green; Amit G Singal; Elliot B Tapper; Akbar K Waljee; Richard K Sterling; Jordan J Feld; David E Kaplan; Tamar H Taddei; Kristin Berry
Journal:  Gastroenterology       Date:  2019-07-26       Impact factor: 22.682

5.  Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.

Authors:  V Knop; D Hoppe; T Welzel; J Vermehren; E Herrmann; A Vermehren; M Friedrich-Rust; C Sarrazin; S Zeuzem; M-W Welker
Journal:  J Viral Hepat       Date:  2016-08-08       Impact factor: 3.728

6.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Peter Richardson; Jennifer Kramer
Journal:  Hepatology       Date:  2016-04-19       Impact factor: 17.425

7.  Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.

Authors:  B J Thomson; G Kwong; S Ratib; M Sweeting; S D Ryder; D De Angelis; R Grieve; W L Irving
Journal:  J Viral Hepat       Date:  2007-12-11       Impact factor: 3.728

8.  Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.

Authors:  Mònica Pons; Sergio Rodríguez-Tajes; Juan Ignacio Esteban; Zoe Mariño; Víctor Vargas; Sabela Lens; Maria Buti; Salvador Augustin; Xavier Forns; Beatriz Mínguez; Joan Genescà
Journal:  J Hepatol       Date:  2019-10-17       Impact factor: 25.083

9.  Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.

Authors:  Suraj A Sharma; Matthew Kowgier; Bettina E Hansen; Willem Pieter Brouwer; Raoel Maan; David Wong; Hemant Shah; Korosh Khalili; Colina Yim; E Jenny Heathcote; Harry L A Janssen; Morris Sherman; Gideon M Hirschfield; Jordan J Feld
Journal:  J Hepatol       Date:  2017-08-24       Impact factor: 25.083

Review 10.  Review of survival analyses published in cancer journals.

Authors:  D G Altman; B L De Stavola; S B Love; K A Stepniewska
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.